Novomix 30 Penfill (Insulin Aspart)

Insulin aspart, the active ingredient in Novomix 30 Penfill, is a rapid‑acting insulin analog presented as a pre‑filled pen for subcutaneous use. It lowers blood glucose in people with diabetes mellitus. GNH USA supplies Novomix 30 Penfill as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

GNH USA supplies Novomix 30 Penfill as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Novomix 30 Penfill is a rapid‑acting insulin analog that acts on the glucose regulation pathway in diabetes management. - Type 1 diabetes mellitus: improves post‑prandial glucose control. - Type 2 diabetes mellitus: assists in achieving target fasting and post‑meal glucose levels. - Gestational diabetes mellitus: helps maintain maternal blood glucose within recommended ranges.

Novomix 30 Penfill may cause a range of adverse reactions.

Common Side Effects: - Hypoglycaemia: low blood glucose levels. - Injection site reactions: redness, swelling, or itching. - Lipodystrophy: localized fat tissue changes. - Weight gain: increase in body weight.

Serious or Rare Side Effects: - Severe hypoglycaemia with neuroglycopenic symptoms. - Allergic reactions: urticaria, angio‑oedema, anaphylaxis. - Hypersensitivity to the insulin or excipients. - Edema: peripheral swelling. - Vision‑related   ...

Novomix Store  ... … … ... … … … … … … … … … … … … … … …